<DOC>
	<DOCNO>NCT01406275</DOCNO>
	<brief_summary>This post-marketing surveillance study CLAVAMOX® design collect ass information proper use , safety efficacy , actual use condition , target pediatric Japanese patient disease ( superficial skin infection , deep skin infection , lymphangitis , lymphadenitis , chronic pyoderma , pharyngitis , laryngitis , tonsillitis , acute bronchitis , cystitis , pyelonephritis ) otitis medium . ( `` CLAVAMOX '' trademark GlaxoSmithKline group company . )</brief_summary>
	<brief_title>Special Drug Use Investigation CLAVAMOX® ( Amoxicillin/Clavulanate ) Pediatrics Dry Syrup ( Every Indication Excluded Otitis Media )</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Pediatric subject diseases superficial skin infection , deep skin infection , lymphangitis , lymphadenitis , chronic pyoderma , pharyngitis , laryngitis , tonsillitis , acute bronchitis , cystitis pyelonephritis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>